We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Tamoxifen Ruling Eases Hatch-Waxman Settlements

Law360 (November 11, 2005, 12:00 AM EST) -- On November 2, 2005, the United States Court of Appeals for the Second Circuit affirmed the dismissal of complaints filed by consumers and others in civil antitrust litigation relating to anti-cancer drug, Tamoxifen. In re Tamoxifen Citrate Antitrust Litigation, No. 03-7641 (2d Cir., November 2, 2005). The complaints asserted that AstraZeneca and Barr Laboratories violated federal and state antitrust laws when they settled Astra’s patent litigation against Barr. That patent litigation was instituted under the Hatch-Waxman Act of 1984, 21 U.S.C. §355 (j)(5)(B)(iii), following Barr’s filing...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.